Rubedo Life Sciences
Biotechnology company developing a prodrug discovery platform for creating "smart drugs" that selectively activate in senescent cells implicated in age-related diseases, enabling targeted elimination of harmful cells.
Notes
Rubedo Life Sciences is a biotechnology company developing a novel prodrug discovery platform aimed at creating "smart drugs" that selectively activate in target cells implicated in age-related diseases. The company's technology enables the development of senolytics - drugs that selectively eliminate senescent cells, which accumulate with age and contribute to various age-related pathologies.
The company's prodrug approach allows for systemic administration while achieving local activation only in senescent cells, potentially reducing side effects and improving therapeutic windows compared to traditional senolytic approaches.
Rubedo Life Sciences has received funding from VitaDAO, a decentralized autonomous organization focused on longevity research.
Team
- Marco Demaria, Ph.D. - Co-founder & Scientific Advisor
- Professor at University Medical Center Groningen
- Amit Sharma - Chief Executive Officer
Additional Research Findings
- Prodrug discovery platform for senolytics
- "Smart drugs" technology - selective activation in target cells
- Funded by VitaDAO
- Focus on age-related disease therapeutics
- Senescent cell targeting approach
- Sunnyvale, California headquarters
- Scientific foundation from University of Groningen research
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| VitaDAO | Decentralized (Global) | dao | seed | 7 |